

O c t o b e r 1 9 , 2 0 0 9

Hisamitsu Announces FDA Approval of its Fentanyl Transdermal System for Management of Chronic Pain (Development code: HFG-512)

Hisamitsu Pharmaceutical Co., Inc. (Hisamitsu; TSE:4530) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for its matrix Fentanyl Transdermal System (Development Code: HFG-512) on October 16,2009.

Hisamitsu's Fentanyl Transdermal System is a matrix type transdermal patch containing Fentanyl, designed for management of persistent moderate to severe pain.

The Fentanyl Transdermal System will be distributed in the U.S. by Apotex Corp. under an exclusive distribution agreement executed between Hisamitsu and Apotex, and manufactured by Hisamitsu at its factory in Carlsbad, California.

This is the first approval of an Rx product received by Hisamitsu in the U.S., and marks a significant milestone in the company's entry to the U.S. Rx market.

Through the distribution of its Fentanyl Transdermal System, Hisamitsu and Apotex will provide patients who suffer from chronic pain with a safe and high quality treatment option for the improvement of Quality of Life.

<Note to Editor>

About Fentanyl Transdermal System

The Fentanyl Transdermal System developed by Hisamitsu is a 72 hour matrix type transdermal patch containing Fentanyl, designed for management of persistent moderate to severe pain. Annual sales for the total Fentanyl transdermal patch market in the U.S., which is the targeted market for Hisamitsu's Fentanyl Transdermal System, are approximately \$1.2 billion.

About Apotex

Apotex Corp. is a subsidiary of Apotex Inc.

Apotex has over 6,000 employees worldwide and produces over 300 medicines in 4000 dosages, in 21 facilities in North America. Apotex is in the top 10 generic companies in the USA and plans to spend \$ 2 billion in research and development over the next 10 years. It presently has 600 products in development and produces quality affordable medicines for healthcare systems in 115 countries.